ILM ATS

Lung screening only identifies 20% of lung nodules!
We ensure you SEE the other 80%.

Our Discover360 Platform leverages Workflow Conscious AI^TM to:

Provide end-to-end lung nodule patient management.
Increase follow-up compliance by screened patients.
Ensure all lung nodule patients receive the timely care they need.
Eliminate gaps in care, save lives and create new revenue opportunities.
Prioritize patient follow-up care according to health system care guidelines.

Realize end-to-end improvements in the identification, management, and surveillance of all lung nodule patients - whether identified incidentally or during screening.

We are excited to exhibit at ATS 2023.

Attending the show?

Schedule a demo below to learn how we can help:

Find us in booth #1837

Realize end-to-end improvements in the identification, management, and surveillance of all lung nodule patients – whether identified incidentally or during screening.

Find our booth in this interactive map

Don’t Miss Our Guru Bar Talk at ATS!

When: Monday, May 22 at 11:30 a.m.

Where: Guru Bar 1

Title: Lung Nodule Surveillance: Why Screening Alone is Not Enough.

CLICK HERE TO LEARN MORE

Setting up an Incidental Lung Nodule Program?

Success requires aligning the right people, process, and technology

Low dose computed tomography lung screening has received much attention since the US Preventive Task Force published its initial recommendations in 2013. Because of the proven benefits, those recommendations were expanded in 2021.

To date, however, little attention has been paid to the importance of the ongoing surveillance and management of patients with incidentally found lung nodules. This creates a significant opportunity to improve the care of all such patients by developing a comprehensive incidental lung nodule surveillance program.

Read this white paper to understand the following three key points:

The value and insights that can be gained from an incidental lung nodule surveillance program.
The issues that must be considered when implementing an incidental lung nodule surveillance program.
The key features of an incidental lung nodule patient surveillance solution.

Thank you for requesting this document.

An email has been sent from sales@illumiate.ai with the PDF attached.

Stay tuned for additional industry whitepapers from Illuminate.

Oops! Something went wrong while submitting the form.

Lung screening only identifies 20% of lung nodules!We ensure you SEE the other 80%.